You are here

Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

Last updated on March 28, 2020

FOR MORE INFORMATION
Study Location
Gothenburg, , SE-413 45 Sweden
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transplantation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Transplantation patients treated with sirolimus (Rapamune).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients must be able to give informed consent.

NCT00195195
Pfizer
Completed
Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries
Official Title A Rapamune Follow-up Registry in Transplant Recipients in the Nordic Countries, "Wrap-up"
Brief Summary The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Transplantation patients treated with sirolimus.
Condition Transplantation
Intervention Drug: Sirolimus
Transplantation patients treated with sirolimus who consent to participate in the study (register)
Other Name: Rapamune
Study Groups/Cohorts 1
Sirolimus
Intervention: Drug: Sirolimus
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: January 26, 2012)
66
Original Enrollment
 (submitted: September 12, 2005)
200
Actual Study Completion Date June 2008
Actual Primary Completion Date June 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Transplantation patients treated with sirolimus (Rapamune).

Exclusion Criteria:

  • Patients must be able to give informed consent.
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Sweden
Removed Location Countries  
 
Administrative Information
NCT Number NCT00195195
Other Study ID Numbers 0468-101157
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Wyeth is now a wholly owned subsidiary of Pfizer
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Wyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date January 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now